Teva Pharmaceutical Industries Ltd.. (6/6/17). "Press Release: Teva to Present at the Jefferies 2017 Global Healthcare Conference". Jerusalem.

	Region	New York, NY
	Country	United States (USA)
	Organisation	Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA)
	Group	Teva (Group)
	Organisation 2	Jefferies LLC
	Group	Leucadia (Group)
	Product	Jefferies 2017 Global Healthcare Conference New York
	Product 2	pharmaceutical
	Index term	Teva–Leucadia: investor conference, 201706 supply service Teva presents at Jefferies Healthcare Conference in New York
	Person	Peterburg, Yitzhak (Teva 201702– Interim CEO)
	Person 2	Hayden, Michael R. (Forbion 202203– Venture Partner + Prilenia Therapeutics 202006– CEO former CSO at Teva)

Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) will host a live audio webcast at the Jefferies 2017 Global Healthcare Conference in New York, NY.

When:
Wednesday, June 7, 2017 at 2:30 PM ET

Who:
Dr. Yitzhak Peterburg, Interim President & CEO,
Dr. Michael Hayden, President of Global R&D & Chief Scientific Officer,
Dipankar Bhattacharjee, President & CEO Global Generic Medicines, Teva Pharmaceutical Industries Ltd.

Where:
http://ir.tevapharm.com

How:
Live over the Internet – log on to the Web at the address above and register for the event (approximately 10 minutes before). An archive of the webcast will be available on Teva’s Website at http://ir.tevapharm.com.

About Teva

Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) is a leading global pharmaceutical company that delivers high-quality, patient-centric healthcare solutions used by approximately 200 million patients in 100 markets every day. Headquartered in Israel, Teva is the world’s largest generic medicines producer, leveraging its portfolio of more than 1,800 molecules to produce a wide range of generic products in nearly every therapeutic area. In specialty medicines, Teva has the world-leading innovative treatment for multiple sclerosis as well as late-stage development programs for other disorders of the central nervous system, including movement disorders, migraine, pain and neurodegenerative conditions, as well as a broad portfolio of respiratory products. Teva is leveraging its generics and specialty capabilities in order to seek new ways of addressing unmet patient needs by combining drug development with devices, services and technologies. Teva's net revenues in 2016 were $21.9 billion. For more information, visit www.tevapharm.com.

Teva Pharmaceutical Industries Ltd.

IR Contacts:
United States
Kevin C. Mannix, 215-591-8912
or
Ran Meir, 215-591-3033
or
Israel
Tomer Amitai, 972 (3) 926-7656

or

PR Contacts:
Israel
Iris Beck Codner, 972 (3) 926-7246
or
United States
Denise Bradley, 215-591-8974

Record changed: 2023-06-05